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Abstract
Background: Melanoma is a malignant skin cancer and is one of the most aggressive malignancies in humans. Heavy metals, including 
lead, are known to cause cellular toxicity and have been studied for their potentials to induce apoptosis in tumor cells. Since selenium is 
considered to act protectively in cases of lead poisoning, this study focused on the effects of sodium selenite and lead chloride, both alone 
and combined, on melanoma cell apoptosis. Methods: This study was carried out by doing cell culture of melanoma cells (B16-F10 cell 
line) and using C57BL/6 mice. Melanoma cells suspended in lead (II) chloride, sodium selenite, or lead (II) chloride + sodium selenite so-
lutions were injected subcutaneously to mice to induce tumor growth. After 12 days, tumors were excised and measured, followed by flow 
cytometry and a statistical analysis using a one-way ANOVA. Results: In the group of mice receiving a single injection of melanoma cells 
suspended in 10 µmol/l of lead (II) chloride, the growth of tumor was significantly slower than in the control group. In mice treated with 
lead (II) chloride 50 µmol/l and 100 µmol/l, no tumor was visible at the end of the experiment. With a single injection of lead (II) chloride 
and sodium selenite at concentrations ≥ 10 µmol/l, the weight and size of the tumor were substantially smaller than in the control group. 
Conclusion: The effect of lead (II) chloride on melanoma induction is dependent on the concentration of lead (II) chloride. Future applica-
tions may include the use of lead (II) chloride to increase apoptosis and necrosis in tumor cells and thus suppress tumor cells proliferation.
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Introduction
Modern life and industrialization bring comfort and convenien-
ce, but also entail the increase of exposure to harmful substan-
ces, including heavy metals. Different metals induce different 
conditions, depending on the concentration and the type of 
exposure.1 Heavy metals are considered to be toxic due to their 
ability to induce a variety of deleterious effects. The toxicity 
caused by heavy metals, such as arsenic (As), mercury (Hg) 
and lead (Pb), has already been recognized by health authori-
ties as occupational health hazards. 
Heavy metals are chemically reactive and bioaccumulative, 
which means that the human body is not able to effectively eli-
minate them, differing them from other potential toxic agents. 
The consequences of exposures to lead, cadmium (Cd), and 
mercury and the consequent pathological changes in the liver, 
kidney and bone are well documented.2-10 Moreover, thorium 
(Th), cadmium, lead, chromium (Cr), nickel (Ni), and beryllium 
(Be) are heavy metals with confirmed carcinogenic effects in 
animals and humans.11-15 Thus, there is an increasing evi-
dence that the exposure to heavy metals could be associated 
with the occurrence of lung, liver, bladder, kidney, colon and 
skin cancer.15 
One of the most widely used heavy metals is lead. This metal 
can enter the body through inhalation, ingestion and dermal 
exposure. The induction of inflammatory processes is one of 
the various effects caused by lead. The toxicity of lead results 
from its interaction with the functional groups of enzymes.16 
Unfortunately, human exposure to lead is an inevitable conse-
quence of human life, since exposures occur mainly from two 
sources: occupational and environmental. Lead is a toxic heavy 
metal which is likely to lose electrons easily, forming positively 
charged ions that tend to be soluble in biological fluids. It has 
higher affinity for groups containing sulfur, such as sulfhydryl 
(SH), than for ones containing oxygen.17 Lead forms covalent 
bonds, causing changes in the properties of sulfhydryl-con-
taining enzymes, such as solubility, dissociation, the relative 
affinity to receptors, distribution and excretion.17 Lead toxicity 
affects several organ systems, including nervous, hematopoie-
tic, renal, endocrine and skeletal systems.17
Melanoma is a malignant tumor which originates from mela-
nocytes, cells that produce the pigment melanin that gives 
color to skin, hair and eyes. The incidence of this skin cancer 
has been increasing more rapidly than any other cancer type. 
It is one of the most aggressive malignancies in humans and 
is responsible for 60% to 80% of skin cancer deaths.18 This 
is not only because of its incidence and propensity to affect 
young adults, but also because of its high metastatic potential, 
aggressive clinical behavior, and extraordinary resistance to 
the currently available chemotherapeutic and immunological 
treatments.18 During the development of malignant melanoma, 
there is a complex interaction of environmental and endoge-
nous (genetic) factors, including the deregulation of cell proli-
feration, the programmed cell death (apoptosis),19 and cell-cell 
interactions.20
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Selenium and its compounds, both inorganic and organic, have 
recently attracted oncologists’ attention after several epidemio-
logical studies revealed an inverse correlation between the in-
take of selenium and the incidence of cancer.21 Selenium has 
quite important biological and biochemical functions in organis-
ms because of its antioxidant properties, preventing the forma-
tion of free radicals that cause DNA damage and promote tumor 
genesis. It also is a moderate antagonist for the toxic effect on 
the body of many heavy metals such as arsenic,22 cadmium,23 
mercury,24-25 and lead.26 Selenium is used in methylated forms, 
which are less toxic and still have effects on carcinogenesis,27 
and more than 90% of the experiments have used sodium se-
lenite.28 Selenium confers protection, in part by inducing cellu-
lar free radical scavenging systems and by enhancing peroxide 
breakdown.29 Thus, selenium enhances the capacity of the cell 
to cope with oxidative stress.29 The selenoproteins (Se-P) may 
be useful in the prevention of cancers which are associated with 
persistent chronic inflammation and infection, since Se-P are 
presumed to be involved in alleviating the toxicity of heavy me-
tals.30-32 Some Se-P have important enzymatic functions because 
they generally contain selenocysteine (SeC) in the active site, as 
well as cysteine (Cys) residues, indicating that it is capable of 
transporting selenium and bind to heavy metals.24 Thus, we be-
lieve that Se-P has three separate roles: (1) antioxidant defense; 
(2) a role in the transport of selenium; (3) a protective role as 
a natural chelator of heavy metals. In addition, the anti-tumor 
activity of selenium is directly related to its antioxidant activity, 
acting on the protection of Cys residues of reduced glutathione 
(GSH), which is considered to be the most important compound 
in the detoxification of carcinogens.24 Apoptosis and necrosis 
are two types of cell death that can occur due to in vivo or in 
vitro exposure to cadmium or lead,33 which caused an increase 
in lyses or necrosis. Selenium provides a significant protection 
against cadmium-induced apoptosis.34 
Given the facts that lead is toxic by causing mainly necrosis 
and that selenium is an antagonist to the toxic effects of many 
heavy metals, the aim of this study was to investigate the po-
tential of lead for the treatment of melanoma and the potential 
protective role of selenium against the toxic effects of lead.  We 
hypothesise that lead can be used to treat melanoma, along 
with selenium to work against the toxic effects of lead.
Methods
C57BL/6 mice were used in this study in view of the similarity 
between melanoma in mice and melanoma in human and the 
relative ease of melanoma induction in mice compared to other 
animal models.35 The investigators who performed the subcuta-
neous injection, tumor growth measurements, flow cytometry, 
and the statistical analysis were not blinded to group allocation.
Animals
Seventy eight female C57BL/6 mice (Charles River Laboratories 
España S.A., Barcelona, Spain) between 6-8 weeks of age and 
weighing about 19.5 ± 2.0 g were kept under standard housing 
conditions (49 x 34 x 16 cm autoclavable polypropylene boxes 
with a wire lid and built-in feeder and water drinker, 12-hour 
light cycles from 7 a.m. to 7 p.m., and controlled humidity and 
temperature) and with food and water ad libitum. The animals 
were assigned randomly into 10 treatment groups (six mice per 
group) and one control group (n = 18) (Table 1).
All animals were treated in accordance with the European 
Council Directive 2010/63/EU on the protection of animals used 
for scientific purposes. After the experiments, the animals were 
euthanized with a lethal injection of lead, since it was conside-
red to be the way which implied the minimum pain, suffering 
and distress (Article 6 of the European Directive).
Reagents
Sodium selenite and lead (II) chloride were purchased from 
Sigma Chemical Co. (St. Louis, Missouri, USA) at four concen-
trations: 1, 10, 50, and 100 µmol/L. The suspensions were pre-
pared in 500 µl of sterile phosphate-buffered saline (PBS) and 
resuspended with 5 x 105 melanoma cells. These suspensions 
were injected into the air pouch of the mice, which is described 
later in this section.
Cell Culture
Melanoma cells (B16-F10 cell line) were purchased from ATCC 
(Manassas, Virginia 20110-2209, USA). The cells were cultivated 
in Dulbecco’s modified Eagle’s medium (DMEM) (Life Technolo-
gies, Inc., Rockville, Maryland, USA), which was supplemented 
with 10% fetal bovine serum (FBS) (HyClone, Logan, Utah, USA) 
and contained 100 units/ml of penicillin, 100 µg/ml streptomy-
cin, and a solution of nonessential amino acids (Life Technolo-
gies, Inc.). The cells were maintained at 37ºC in a humidified 
atmosphere of 5% CO2 / 95% air. This was the first step of the 
entire experiment.
Subcutaneous Injection
In order to form a subcutaneous air pouch, 5 ml of sterile 
air was injected into the subcutaneous dorsal midline of the 
animals 10 days after the cell culture was started. After three 
days, 2.5 mL of sterile air were reinjected in order to maintain 
the open space. This method was adapted from previously pu-
blished experiments.8,36 Four days after the first injection, the 
following suspensions were injected directly into the air pouch:
• Control group: 300 µl of PBS + 300 µl of melanoma cells 
(concentration 5 x 105); 
• Group I: 300 µl of lead (II) chloride + 300 µl of melanoma 
cells (concentration 5 x 105); 
• Group II: 300 µl of sodium selenite + 300 µl of melanoma 
cells (concentration 5 x 105); 
• Group III: 300 µl of lead (II) chloride and sodium selenite 
+ melanoma cells (concentration 5 x 105).
For Groups I and II, we used lead (II) chloride or sodium sele-
nite of four different concentrations: 1, 10, 50, and 100 µmol/L. 
For Group III, the molar ratio between selenium and lead was 
1:1, as referenced in some recent studies regarding the molar 
ratio of selenium in tissues.6
Tumor Growth
Measurements of body weight as a surrogate measure for tu-
mor weight were made 0, 2, 5, 7, 9, and 12 days after treat-
ment. On the 12th day, we aseptically excised, weighed, and 
measured the size of the tumors. For calculation of tumor vo-
lume, the following formula was used: 
Tumor volume (cm3) = 0.52 (length x width x height).38
Flow Cytometry
For cytometric analysis, each subcutaneous exudate sample, 
Sá I, et al. The Effects of Lead and Selenium on Melanoma Induction
The International Journal of Medical Students Int J Med Students   •   2015  |  Apr-Aug  |  Vol  3  |  Issue 285
IJMS
International Journal of 
Medical Students Original Article
retrieved from the already excised tumor mass via a needle 
introduced in the edema, was stained with TACSTM Annexin 
V-FITC Apoptosis Detection Kit (R&D Systems, Minneapolis, Min-
nesota, USA) for 15 minutes. This product detects the externa-
lization of phosphatidylserine in apoptotic cells using recom-
binant annexin V conjugated to green-fluorescent FITC dye and 
necrotic cells using red-fluorescent propidium iodide (PI). After 
treatment with both probes, apoptotic cells show green fluo-
rescence, dead cells show red and green fluorescence, and live 
cells show little or no fluorescence. After staining, the tumor 
cells were washed twice and suspended for flow analysis by 
fluorescence activated cell sorting (FACS) in a medium contai-
ning propidium iodite (Sigma). Data were collected on cells se-
lected by forward light scatter (FSC) and PI gating in a FACScan 
analyser (Becton Dickinson) with CellQuest software.
Statistical Analysis
The statistical comparison between the data collected from ex-
perimental and control groups was performed using a one-way 
ANOVA. The numerical data are presented as means ± standard 
deviations, unless otherwise specified. Statistical significance 
was considered for p<0.05. All statistical analyses were perfor-
med using SPSS 14.0® for Windows.
Results
Our observations showed that 2-3 days after the injection of 
melanoma cells into the air pouch of the mice, tumor started to 
develop and a protruding mass was clearly seen under the skin 
around five days after injection. Between 5-12 days after treat-
ment with lead (II) chloride, the changes in the body weight of 
the mice treated with lead (II) chloride 1 µmol/l were similar 
to that of the control group. For groups that were treated with 
lead (II) chloride 10, 50 and 100 µmol/l, no significant changes 
in body weight were observed, and the mean body weight on 
day 12 was significantly smaller than the control group (p<0.05) 
as a result.  In contrast, for groups that were treated with 
sodium selenite 1, 10, 50 and 100 µmol/l, no significant diffe-
rences were observed between the body weight of the treated 
mice and the control group (Figure 1). 
After 12 days of treatment, we excised, weighed and measured 
the size of the tumors (Table 2). After an injection of 1 µmol/l of 
lead (II) chloride, the tumor continued to develop. In contrast, 
mice treated with 10 µmol/l of lead (II) chloride had smaller 
tumor weight and tumor volume compared to the control group. 
For mice treated with lead (II) chloride at a concentration higher 
than 50 µmol/l, no tumor mass was recovered, and the differen-
ces with the control group were significant (p<0.05). The tumor 
weight and volume of mice treated with sodium selenite of all 
concentrations were similar to the control group (Figure 2). 
The tumor weight and volume for mice which were administe-
red a single injection of equimolar (1:1) lead (II) chloride and 
sodium selenite 10 µmol/l were smaller than those of control 
groups. No tumor mass could be recovered from mice injec-
ted with the combination suspension at a concentration of 100 
µmol/l (Figure 3). 
The percentage of apoptosis and necrosis in melanoma cells 
after 12 days of treatment with 1 µmol/l of lead (II) chloride and 
with 1, 10, 50 and 100 µmol/l of sodium selenite was around 
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Table 1. Treatment Groups.
Lengend: * Control group, † Treatment group I: PbCl
2
, ‡ Treatment group II: 
Na
2
SeO
3
, § Treatment group III: PbCl2 + Na
2
SeO
3
.
Treatment groups n Tumor weight (g)† Tumor volume (cm3)†
Control 18 5.43 (1.31) 4.98 (2.14)
PbCl
2
1 µmol/l 6 4.37 (1.38) 4.21 (1.26)
10 µmol/l 6 0.32 (0.26) 0.07 (0.07)
50 µmol/l 6 0 (0) 0 (0)
100 µmol/l 6 0 (0) 0 (0)
Na
2
SeO
3
1 µmol/l 6 3.95 (1.18) 3.84 (2.22)
10 µmol/l 6 3.16 (1.19) 2.88 (1.26)
50 µmol/l 6 2.69 (1.07) 2.28 (1.05)
100 µmol/l 6 2.65 (0.91) 1.95 (1.43)
Table 2. Tumor Weight and Volume after 12 Days of Treatment.
Lengend: † Data presented as mean ± Standard Deviation.
Figure 1. Changes in Body Weight of Mice Following Lead 
(II) Chloride or Sodium Selenite Injections.
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10%, the same as in the control group. When the melanoma 
cells were treated with a concentration of 10 µmol/l of lead (II) 
chloride, the percentage of apoptosis was around 20% and the 
percentage of necrosis was nearly 80%. With a concentration 
of 50 µmol/l of lead (II) chloride, the percentage of apoptosis 
was lower at 10%, while the percentage of necrosis was higher 
at almost 90%. Finally, with a concentration of 100 µmol/l of 
lead (II) chloride, there was almost 100% of necrosis (Figure 4).
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that are in accordance with previous studies.39 Similar findings 
were not observed following treatment with sodium selenite. 
Lead and several inorganic lead compounds appear to have 
deleterious effects on skin, muscles, and the immune system.40 
Lead has already been used to induce cell death in human 
neuroblastoma cells in previous studies.41 When neuroblastoma 
cells were treated with lead alone, they exhibited a significant 
decrease in their viability.42 Similar effects were observed in 
the present study:  the development of melanoma appears to 
be negatively associated with lead (II) chloride concentration.
In contrast to findings of previous studies which suggested 
the potential of selenium as a cancer preventative agent and 
an anti-metastasis agent,43 our study did not find a significant 
effect of selenium on tumor development. When the tumor was 
treated with an equimolar injection of lead (II) chloride and so-
dium selenite, the weight and total volume of the tumor were 
smaller than the control group at a concentration of 10 µmol/l, 
and no tumor was recovered at a concentration of 100 µmol/l. 
The effects of lead (II) chloride or lead (II) chloride + sodium 
selenite on tumor growth were similar.
Selenium has a protective role against the development of 
tumors because it delays the oxidative damage in DNA and 
lipids as well as regulates cellular and molecular events that 
are essential for cell growth and carcinogenesis.44 Selenium is 
also considered to protect the organism in cases of poisoning 
with lead, mercury and cadmium.45 When melanoma cells were 
treated with lead (II) chloride ≥ 50 µmol/l, the percentage of 
cell with necrosis increased. However, when they were treated 
with the same concentrations of sodium selenite, no significant 
differences in the percentages of apoptosis and necrosis were 
observed between the treatment groups and the control group. 
Thus, our findings were in accordance with other experiments 
which showed that the cadmium and lead caused an increase 
of lyses or necrosis.33
Given the facts that chemotherapy and radiotherapy eliminate 
tumor cells by inducing apoptosis and that melanocytes are 
resistant to apoptosis,46-48 it is important to study the possibility 
of eradicating malignant tumor cells via necrosis induced by 
lead in certain concentrations. Nonetheless, it is also important 
to keep in mind that necrosis triggers inflammatory processes 
and thus it is vital to use an antagonist (such as selenium) to 
reduce the toxic and inflammatory effects of lead. Hence, the 
main goal is to make a compromise between the lead con-
centration and tumor cell destruction without causing severe 
inflammation problems as well as lead intoxications. This can 
be counteracted by using selenium as a lead toxicity detoxifier. 
Our study findings demonstrated the potential of lead as a 
possible therapy for melanoma via the induction of necrosis, 
the accompanying inflammatory reactions of which could be 
counteracted by administering lead in combination with sele-
nium, a lead antagonist. Future studies conducted using other 
techniques as well as full pathological studies are necessary to 
explore further the effects of lead and selenium on melanoma 
induction.
Discussion
Our study found that both the weight and total volume of tu-
mors in mice treated with lead (II) chloride tends to be smaller 
with the increasing concentration of lead (II) chloride, results 
Figure 2. Tumor Weight and Volume after 12 days of Treat-
ment with Lead (II) Chloride or Sodium Selenite.
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Figure 3. Tumor Weight and Volume after 12 Days of Treatment with a Sin-
gle Injection of Lead (II) Chloride (PbCl
2
) and Sodium Selenite (Na
2
SeO
3
).
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Figure 4. The Percentages of Apoptosis and Necrosis after 12 
Days of Treatment with Lead (II) Chloride or Sodium Selenite.
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